Author Archive

Post Archives

Scaling Diverse and Inclusive Tech Businesses

Wednesday, October 25, 2023
11:00am – 12:00pm

In partnership with B2BeeMatch, Tech Canada Advocates and London & Partners.

Details to be announced.

The English-Speaking Union Lecture & Reception

Tuesday, September 19, 2023
Reception: 5:00pm
Lecture: 5:45pm


The Philadelphia Branch of the English-Speaking Union is honored to hose Dr. Andrew Lownie at a Speaker event on Tuesday, September 19, 2023 at Carpenters’ Hall.

After the Abdication: The Duke and Duchess of Windsor in Exile

The 1936 Abdication Crisis – when Edward VIII gave up his throne for the woman he loved – is well-known, but what happened to them afterwards? Drawing on secret sources and his book, Andrew Lownie tells their story, from their pro-Nazi views and controversial wartime posting to the Bahamas to their post war life in Palm Beach and New York.

Fall 2023 BABCPHL New Members

Club Member:

Baker Tilly US, LLP
Robert Jaffe
Director, Growth Strategies
P: 215-972-2521
1650 Market Street
Suite 4500
Philadelphia, PA 19103

Baker Tilly US, LLP (Baker Tilly) is a leading advisory CPA firm, providing clients with a genuine coast-to-coast and global advantage in major regions of the U.S. and in many of the world’s leading financial centers – New York, London, San Francisco, Los Angeles and Chicago. Baker Tilly is an independent member of Baker Tilly International, a worldwide network of independent accounting and business advisory firms in 145 territories, with 41,000 professionals and a combined worldwide revenue of $4.7 billion. Visit or join the conversation on LinkedIn, Facebook and Twitter.

Corporate Members:

ieso Digital Health Inc.
Deborah Cleary
Head of Payer Development
P: +44 (01223) 752574
101 Federal Street
Suite 900
Boston, MA 02110

Jodi Prohofsky
Chief Operations Officer (US)

Little is known about what makes mental healthcare successful and why. We’re blending data science and deep clinical expertise, to learn what helps people access the right treatment and recover. We use this knowledge to create fully scalable, highly personalised, digital solutions that help prevent, treat and manage poor mental health.

Our pioneering discoveries in mental healthcare are improving how the world understands and treats mental health. From the beginning, we’ve placed patients at the heart of everything we do, and believe in a world where everyone has access to effective mental healthcare that is right for them at the time they need it.

Grace Fitts
Director, Client Advisory Services | Private & Corporate Collections
P: 267-414-1254
2400 Market Street
Suite 304
Philadelphia, PA 19103

As America’s oldest auction house, Freeman’s has been an active part of the auction world and art market for more than 215 years. While still ingrained within the heart of Philadelphia–a city which the house has proudly called home for over two centuries–Freeman’s stays connected to the global art scene through its extensive client network, regional representatives throughout the United States, and an ongoing marketing alliance with Lyon & Turnbull, one the longest established fine art and antiques auction houses in the United Kingdom. Freeman’s illustrious history, familiarity with the market, dedicated team of specialists, and relentless focus on service have resulted in an international reputation for achieving exceptional prices and client satisfaction. In addition to their year-round auction schedule that spans specialist departments, Freeman’s supports private and corporate collectors with additional services, including Trusts and Estates, Appraisals, and Private Sales.

Educational, Arts & Charitable Institution Member:

DBE National Society
Susan J. Gerrity
National President
E: or
P: 610-220-6074

The Daughters of the British Empire (DBE) is a charitable, non-profit, non-political, non-sectarian, voluntary American society of women of British and Commonwealth birth or ancestry. Its members are professionals, businesswomen, and homemakers with common interests and heritage, who meet regularly for business and social events with the common cause of philanthropy. The society was founded in the United States on March 15, 1909, as the Imperial Order, Daughters of the Empire in the U.S.A., and became the National Society, Daughters of the British Empire in the U.S.A. on April 14, 1920. The National Society is incorporated in the State of Delaware.

The Society is affiliated with the Imperial Order Daughters of the Empire in Canada (IODE); the Victoria League in London, England; and the General Federation of Women’s Clubs in the United States.

For over 100 years, the Daughters of the British Empire in the U.S.A. has been a common bond for women of British heritage living in America. Members, joining together in fellowship, contribute significantly to the good of their local communities and support the retirement homes for men and women established by the DBE.

Individual Member:

David Klucsik
P: 609-516-6764

Affiliated with TALA Communications of Oxfordshire, David Klucsik’s Same Page LLC offers marketing and communications services, specializing in complex, controversial, and emotional issues involving business, industry, science, media, and public policy, often in a crisis context.

McCann Team State of the Residential Real Estate Market

Mid-Atlantic: Continued Growth, Setting it Apart from Other National Regions

Throughout July, the Mid-Atlantic region saw a 3.9% increase in home prices, boosting the median price to $400,000. This made for the strongest price growth since the beginning of this year, going against the trends seen in other national markets.

The summer market has remained strong, a continuation of the patterns previously observed in June. The elevated mortgage rates have not discouraged competition among buyers vying for a property among the historically low levels of inventory. This is according to the Mid-Atlantic July Housing Report released by Bright MLS.

Dr. Lisa Sturtevant, Chief Economist at Bright MLS, has expressed her surprise at the market’s resilience in the face of higher rates and prices. She noted that even first-time buyers are finding ways to navigate the competitive landscape, with tactics like assumable mortgages and seller financing becoming part of the conversation.

Notably, prices saw an uptick across several metropolitan markets including Washington, D.C., Philadelphia, and Baltimore. Median days on the market, indicating the speed of property turnover, remained consistent at seven days in Baltimore, nine days in Philadelphia, and decreased by a day in the Washington, D.C. metro area, making it seven days.

While the summer season typically brings a slight market cooldown due to vacations and travel, there has been no such relief for buyers this summer. The report highlights a significant drop of over 29% in new properties listed across the region. Active listings have also decreased by 19.1%, indicating that the market pace remains rapid. This emphasizes the need for buyers to act swiftly when encountering the right property.

The report further shows that new pending sales have decreased by 13%, and closed sales experienced a 20% decline in the region for July. The limited inventory has also proven to decrease property showings, which saw a nearly 12% reduction compared to the previous year. Despite these declines, the gap in market activity between the current year and the previous year has narrowed.

Looking ahead, Bright MLS anticipates that the fall market in the Mid-Atlantic region will be characterized by ongoing low inventory, stable or potentially rising home prices, and increasing challenges related to affordability. While mortgage rates are projected to decrease slightly, they are expected to hover around 6.5%. Homeowners are less inclined to sell, fearing the loss of their favorable rates. However, listing activity is predicted to show a slight uptick in the coming months. This could be driven by “movers of necessity” and transactions involving non-standard financing options, such as assumable mortgages and seller financing.

Philadelphia Metro Area: Strong Price Growth Despite Affordability Challenges

The residential real estate market in Philadelphia has experienced a steady and promising recent performance. A steady surge in demand for housing coupled with continued low inventory, has caused property prices to continue their upward trend.

In July, the Philadelphia metro area witnessed a median home price of $369,000, just shy of June’s record at $370,000. Price surges extended to all local markets, including Philadelphia County, which had experienced a dip earlier in the year.

Despite affordability challenges, homebuyers remain actively engaged in the Philadelphia market. Although there was a 13.8% drop in showing activity compared to the previous July, the gap in buyer traffic between 2022 and 2023 is gradually narrowing.

While all of this information can be somewhat daunting, it is important to keep in mind that real estate is often a long-term investment and historically has proven to be one of the largest wealth builders amongst Americans!

State of the Commercial Real Estate Market

Philadelphia’s commercial real estate sector has shown remarkable resilience over the past decade, even navigating the pandemic and fluctuating interest rates. Let’s delve into the four key asset classes, highlighting essential terms:

Net Absorption: This measures the change in leased space over a period, showing whether more space was leased or vacated. Positive net absorption indicates lower vacancy, while negative net absorption points to increased vacant space. It’s a gauge of market demand and health.

Cap Rate (Capitalization Rate): This vital metric assesses potential ROI for a commercial property. It’s calculated by dividing net operating income by market value. A higher cap rate may mean higher returns but also higher risk. It helps compare investment options and evaluate income potential.

Vacancy Rate: This shows the percentage of unoccupied or unleased space in a market. Lower rates suggest strong demand, while higher rates indicate oversupply and weaker demand. It’s a way to assess market health and supply-demand balance.

Delivery: In real estate, “delivery” refers to a new construction or development project’s completion, marking its readiness for occupancy. It involves property transfer, signaling its operational state.

Philadelphia’s office market stands strong among top U.S. markets. Its unique employment mix in healthcare, education, and government sustains its resilience. Despite challenges, Philadelphia’s vacancy and availability rates are impressive, with Center City outperforming other central business districts.

Philadelphia’s multifamily market transformed in 2023, with demand retreat and a surge in construction. The market adjusted as projects surpassed demand, causing the vacancy rate to rise. Philadelphia is still able to maintain a lower vacancy rate compared to other metros. Supply-demand dynamics influence rent trends and sales activity.

Philadelphia’s retail market rebounded, driven by consumer savings and spending. Even still, significant retail space remains available. Converting obsolete properties to mixed-use centers is a trend. The suburban market is robust, attracting tenants. Philadelphia’s affordability lures retailers compared to nearby markets, despite challenges in sales volume.

Philadelphia’s industrial market leads the Mid-Atlantic, with high delivery and construction numbers. While annual absorption ranks third, the vacancy rate is rising due to a wave of new projects. Different warehouse sizes experience varying impacts. Financing costs affect sales volume and cap rates.

Philadelphia’s commercial real estate sector exhibits strengths across asset classes, backed by resilience and unique market dynamics.

Meet The Mike McCann Team

Our team of dynamic and motivated professionals consistently keep client satisfaction as our primary focus. Our team of licensed agents are knowledgeable and passionate about Philadelphia’s wide range of neighborhoods and properties. We have been the #1 real estate team in Philadelphia for over three decades, with over 12K homes sold, 3 billion in revenue, and more rewards from the Philadelphia Board of Realtors than anyone else in the city’s history. We target the specific needs of our clients in order to provide them with the resources and expertise they deserve and use our extensive experience to find the ideal location for their perfect home.

Whether you are interested in buying, selling or investing in Philadelphia, the surrounding suburbs, or the Jersey Shore let us be your guide—no one will work harder for you than The Mike McCann Team. Visit our website at or contact us at Office: 215.607.6007 | Cell: 215.778.0901.

Source: Bright MLS July Housing Report: Mid-Atlantic Housing Market Resilient (

Making What’s Next in Medicine: Why Research at Penn Powers Many FDA-Approved Treatments

Since 2017, the FDA approved more than two dozen new therapies with roots at Penn Medicine — almost half of which are first-in-class for their indications. Becoming a hub for drug research and development took a lot more than luck.

The news reached Abramson Cancer Center (ACC) Director Robert Vonderheide, MD, DPhil, at 11 a.m. on August 30, 2017. It was official: That morning, the U.S. Food and Drug Administration (FDA) approved a Penn Medicine-developed personalized cellular immune therapy.

Six hours later, Vonderheide was standing atop a coffee counter in the atrium of the Perelman Center for Advanced Medicine, addressing hundreds of jubilant faculty and staff members who had gathered for a now-iconic “flash mob” celebration of the milestone. Carl June, MD, and a team of scientists, physicians, and other dedicated staff had together turned a dream of using patients’ own immune cells to treat their cancer, into a reality.

Vonderheide called the discovery “a 20-year overnight sensation.” It would be a defining moment for Penn’s identity as a place that incubates and brings to life some of the most transformative modern medical advancements.

The FDA approval of chimeric antigen receptor (CAR) T cell therapy didn’t happen at Penn Medicine by chance. Nor did the others that followed. Since that day, other medical innovations and research that had been underway at Penn Medicine directly influenced at least two dozen more FDA approvals granted to cancer drugs and other medical technologies — giving the stamp of safety and effectiveness needed for these treatments to be widely available to patients outside of clinical trials. Eleven of the medical advancements documented to date represent the first FDA approvals in their classes: eight under cancer, two under gene therapy, and the revolutionary mRNA technology that powers COVID-19 vaccines around the world.

Penn Medicine faculty may lead this crucial work at different points across the continuum of discovery, from conducting pivotal discovery science in the lab which leads to licensing of compounds and technologies by commercial partners, to leading clinical trials of new therapies initially developed outside of Penn.

The list of Penn-linked FDA approvals is growing with each passing year, and for good reason. Science has shifted toward more discoveries based on the underlying mechanism of disease, especially in new cancer drug discovery. Through a particularly robust clinical trial and commercialization infrastructure, Penn has further worked to smooth every part of the path from idea to implementation. And to ensure that state-of-the-art treatments reach the patients who need them, Penn Medicine teams have also kept focus on equity and access during clinical trials and after therapies are approved.

In the long view, Penn’s emergence as a hub for medical advancements that lead to drug research and development is a credit to both the culture and strategic choices going back decades, says Jon Epstein, MD, executive vice dean and chief scientific officer in the Perelman School of Medicine.

“Our leadership has been judicious about investing in a broad portfolio across a pipeline of development that might take 20 or 30 years,” Epstein says. “People here embrace a no-risk, no-reward approach — they aren’t afraid to take the long view and realize you have to back many different ideas to end up with just a few breakthrough therapies.”

Reducing Barriers to Translational Research

Hiring Carl June — whose belief that the immune system could be trained to fight cancer was derided by naysayers — in 1999 is one of the risks Epstein references. At the time, nobody predicted June’s work would change the entire trajectory of cancer care.

June began studying CAR T cell therapy in cancer in the late 1990s, and as signs of success grew, so did the breadth of collaborators at Penn Medicine and Children’s Hospital of Philadelphia (CHOP) who brought the method into clinical trials. It would take nearly two decades to achieve FDA approval of the therapy in 2017 as a treatment for advanced acute lymphoblastic leukemia. The groundbreaking technique involves taking T cells — part of the immune system — from a patient’s blood and engineering them to produce CARs before reinfusing them into the body. These new receptors latch onto unique antigens on the patient’s tumor cells, killing them. Marketed by Novartis as Kymriah, the first CAR T cell therapy has proved lifesaving for many patients whose cancer has relapsed or failed to respond to other therapies. It has since garnered two additional approvals from the FDA to treat other forms of cancer.

Similar stories have played out on campus over and over. Jean Bennett, MD, PhD, and Albert Maguire, MD, were also “risky” hires whose ambitions vexed skeptics when they joined Penn’s Scheie Eye Institute in 1992. But their determination and decades of work from basic science through to clinical trials at Penn and CHOP, paid off; in December 2017, less than four months after approving CAR T, the FDA approved the married team’s treatment for a rare form of congenital blindness called Leber congenital amaurosis. Marketed as Luxturna, the therapy restores patients’ eyesight by injecting a corrective gene directly into their eyes via a viral vector. It was the nation’s first commercialized gene therapy — a term that encompasses a collection of techniques to modify a patient’s DNA — for a genetic disease.

Eighteen months later, approval followed for Zolgensma, a gene therapy using a viral vector developed in the lab of James Wilson, MD, PhD, director of Penn’s Gene Therapy Program and Orphan Disease Center, and studied in trials at CHOP, to correct spinal muscular atrophy — the number one genetic cause of infant mortality.

And in the most ubiquitous novel advance tied to Penn Medicine, in August 2021 the FDA gave its first full approval to an mRNA-based COVID-19 vaccine, which uses technology discovered more than 15 years earlier by longtime research partners Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research, and Katalin Karikó, PhD, an adjunct professor of Neurosurgery.

Recruiting faculty who dream big is essential to drug development, but there are other reasons Penn Medicine has connections to so many cutting-edge therapies. Among the top, says Vonderheide, is a strategic emphasis on translational research and eliminating barriers between laboratories and the clinic.

“Even our building design reflects that value. If you stand in the lobby of the Perelman Center for Advanced Medicine, you’re within 100 yards of the labs where discoveries are being made, the clinics where clinicians are designing clinical trials and patients are getting therapies, and the offices where executives are working out financial models,” he says. “We’re a unified, integrated system committed to making science real for patients.”

Financial investment from the health system is key to moving discoveries toward the clinic and helping more patients, Epstein adds, citing the Perelman School of Medicine’s Clinical Cell and Vaccine Production Facility — where cell and gene biotherapeutics are manufactured to meet regulatory standards — as an example.

“The health system invested in what was only basic research at the time to build the good manufacturing practices facility that is necessary to produce things like CAR T cells safely so they can be put back into humans,” he says. “Facilities like that cost a lot, and most medical schools can’t afford them. But at Penn Medicine we integrate our clinical and research missions intentionally, for the sake of the patients who don’t have the best clinical options today. We can’t afford not to invest back into ongoing scientific discovery.”

Expanding New Categories of Therapies Pioneered at Penn

The FDA approval of a drug doesn’t mean its development ends, particularly in young and still-unfolding categories like cell and gene therapy and mRNA technology. Research around the world has proliferated in these new realms, where Penn Medicine faculty are still striving to push the science forward.

While CAR T cell therapy has revolutionized treatment for hematologic malignancies, researchers are still striving to use it successfully against solid tumors; getting the treatment to penetrate solid masses is one challenge, and it is harder to find unique antigen proteins to target on solid tumor cells. Faculty members are examining ways to overcome these limitations, such as delivering CAR T cells regionally and testing multivalent CARs, which simultaneously bind to multiple targets.

Researchers are also pursuing universal “off-the-shelf” versions of CAR T, which would spare patients from having to donate their own T cells for engineering — saving precious time while ensuring an abundance of high-quality cells to work with. And many are studying CAR T therapy in conditions other than cancer — including Epstein, who is evaluating CAR T cells’ ability to treat fibrosis, which can affect any organ and is a major driver of heart failure.

In terms of gene therapy, most activity to date has tackled rare diseases, but some faculty are on a mission to change that — like cardiologist Kiran Musunuru, MD, PhD, MPH, ML, director of the Genetic and Epigenetic Origins of Disease Program. Musunuru is applying the gene editing technology CRISPR to fight the leading cause of death worldwide: cardiovascular disease. He has found that modifying genes in the liver can permanently reduce a person’s cholesterol levels and protect against heart attack and stroke. Currently in a clinical trial in New Zealand and the U.K., this single shot could eventually work as a heart disease “vaccine.”

And when it comes to mRNA, “we’re working on every imaginable infectious disease,” says Weissman, who back in 2005, alongside Karikó, discovered how to modify mRNA so it could be used safely and effectively in vaccines and therapeutics. Even before COVID-19 struck, Weissman’s lab group had set up mRNA vaccine clinical trials for herpes, HIV, and influenza. The many avenues they are currently exploring include a universal flu vaccine that covers all 20 known subtypes of influenza virus and an all-in-one “pan-coronavirus” vaccine that would be effective against any new variants yet to emerge.

People suffering with a broad range of life-threatening illnesses today hold onto hope that tomorrow will bring a new therapy that will save their life. Across Penn Medicine, researchers are focused on developing new medicines to address their unmet needs.

“With Penn at the forefront, the application of these first-in-class therapies to a broader array of other diseases is just around the corner. Penn Medicine’s scientific impact — and the worldwide attention it commands — have never been greater,” says J. Larry Jameson, MD, PhD, executive vice president of the University of Pennsylvania for the Health System and dean of the Perelman School of Medicine. “It is a tremendous point of pride that innovation born within our laboratories is being deployed to save lives across the world, and we are committed to fostering breakthroughs that will continue to redefine medicine as the 21st century unfolds.”

More About Penn Medical Advancements Leading to FDA Approvals

The Path from Innovation to Implementation. Penn’s infrastructure in both supporting clinical research and forging commercial partnerships smooths the way from idea to approval.

Why New Cancer Treatment Discoveries are Proliferating. The approval of CAR T cell therapy ushered in a new era for cancer treatment.

Putting Biomedical Research Advances Within Reach. Treatments and vaccines are only useful in the hands of the people who need them.

Fall 2023 President’s Letter

Dear BABCPHL Members and Friends,

In Sonnet 18, William Shakespeare wrote, “Summer’s lease hath all too short a date.” While I agree with the Bard and am always personally sad when summer ends, here at the BABCPHL, our fall busy season is in full swing! I hope you had an enjoyable summer, and you are ready to return to networking and business development. It was terrific to see many of you at our sold-out event in July. Please make sure you register for our September, October, and December programs. We expect full houses for our bourbon tasting and international art “back to school” night, our UK/US architecture and built-environment panel discussion, and our 2023 Signature Annual Holiday Lunch – Goal! Transatlantic Commerce & The Business Behind Sports.

We are honored to partner with local and UK leaders to offer this diverse range of programs. The themes of our events mirror exciting happenings in our region and in the UK. Join us to learn more and ensure you are current on the latest news, trends, and commercial opportunities.

The BABCPHL is your connector organization. Active engagement with the BABCPHL offers benefits you cannot attain elsewhere. Don’t miss out! I encourage you to read through this newsletter to meet our newest members, take a deeper dive into some important topics presented by regional Club Level Member, Penn Medicine, and Corporate Member the Mike McCann Team, and to learn more about our upcoming events.

I look forward to seeing you later this week at Freeman’s for our bourbon tasting, in October at Carpenters’ Hall, the oldest craft guild in America, and in December for the best holiday party of the season! An anonymous writer said of summer, “The tans will fade but the memories will last forever.” Please join us at our upcoming events and make even more memories!


Howard M. Silverstone, MBE, CPA, FCA
President, British American Business Council of Greater Philadelphia

Sustainable Business Series: Understanding Energy Efficiency

Friday, September 29, 2023
10:00am – 11:00am 


Businesses have faced unprecedented challenges in 2023 and continue to grapple with the impact of persistent economic shocks, that have already proven to be significant barriers to growth.

Research conducted by the Greater Birmingham Chambers of Commerce highlight the significant pressures that businesses currently face. According to the Greater Birmingham Chambers of Commerce Quarterly Business Report for Q1 of 2023, half of the businesses surveyed across both Manufacturing and Services are expecting to raise their prices in Q2 of 2023. The main reasons cited by businesses for raising prices were labour costs (25%) cost of utilities (23%) and fuel costs (14%).

Indeed, energy efficiency remains a difficult topic for business leaders across the region. As a result, understanding the benefits of energy efficiency measures is vital. As highlighted by the International Energy Agency in their Energy Efficiency 2022 Report, stronger energy efficiency is the best policy to bring down bills.

Join this webinar to understand why energy bills have been persistently high and how businesses are incorporating energy efficiency measures, in response to rising energy bills.

Navigating Cross-Border Tax Considerations in M&A Transactions

Wednesday, September 13, 2023
11:00am – 12:00pm ET | 10:00am – 11:00am CT


Business owners engaged in a sales process face an ever-increasing series of decisions that can have positive or negative tax implications for the business and its owners. Navigating the sales process requires an evaluation of the tax considerations in each jurisdiction where a business operates to maximize deal economics and minimize tax burden. Join us Wednesday, Sept. 13, as our M&A tax leaders discuss:

  • Current trends in M&A sell-side tax diligence across the U.S. and Europe
  • Sell-side strategies and planning opportunities
  • Cross-border tax considerations for multijurisdictional sellers

Transformational Energy Solutions for the Built Environment Webinar

Wednesday, August 23, 2023
12:00pm – 1:15pm

Brought to you in part by the Department of Business and Trade of the British Embassy and the Building Innovation Hub

DBT would like to cordially invite BABA members to a webinar on the 23rd August 2023 at 12.00 PM, sponsored by the Department of Business and Trade at the British Embassy, and the Building Innovation Hub.

This invitation builds upon a successful Green Buildings event held at the British Embassy on May 24th of this year. That event clearly demonstrated the power of collaboration between the USA and the UK in meeting the challenges of NetZero.

You will leave the webinar with a clear, concise understanding of three global best-of-class technologies which have potential cumulative energy savings in the Built Environment of up to 80%. Each of these solutions have the following characteristics:

·      Fully tested and extensively commercially deployed

·      Transformational environmental impact

·      Huge wellness and productivity benefits

·      Priced for ubiquitous, scalable installation

·      Easy fitting, low maintenance

·      Simple, elegant solutions

·      Fast ROI

The adoption of these exciting technologies, will significantly accelerate your progress to your built environment becoming/including high performance buildings, and will further establish your ESG credentials with the public and your stakeholders.

Please RSVP to Brad Collier at

Power of Purpose with Scott Kirby, CEO, United Airlines

Thursday, September 28, 2023
11:00am – 12:00pm EDT
4:00pm – 5:00pm BST


BritishAmerican Business, in partnership with Brandpie, is delighted to welcome you back to our Power of Purpose Series exploring the crosscutting idea of purpose in business. Join us for an exclusive chat with Scott Kirby, CEO, United Airlines, where Scott will share his philosophy on purpose and how in plays a key role in driving United Airlines’ sustainability goals and business strategies.

↑ back to top

The BABCPHL recognizes our Club Level Members:

  • Almac
  • American Airlines
  • Baker Tilly
  • Cigna
  • Cigna
  • Duane Morris
  • EisnerAmper LLP
  • Faegre Drinker Biddle & Reath LLP
  • Forensic Resolutions
  • Johnson, Kendall & Johnson, Inc.
  • Morgan Lewis
  • Penn Medicine
  • Welsh Government